Showing results (91-100 of 181) with videos related to

Sort By:
Pageof 19
Arthritis Research & Therapy|January 15, 2021
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapyDaniel H Solomon, Chang Xu, Jamie Collins, et al.
Rheumatology (Oxford, England)|November 14, 2020
Tuberculosis risk with biologics by screening-guided preventive strategy in rheumatoid arthritis under intermediate tuberculosis burdenAnna Shin, Yun Jong Lee, Eun Bong Lee, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 3, 2016
Gout and Risk of Fracture in Women: A Prospective Cohort StudyJulie M Paik, Seoyoung C Kim, Diane Feskanich, et al.
Arthritis Care & Research|July 18, 2013
Clinical and health care use characteristics of patients newly starting allopurinol, febuxostat, and colchicine for the treatment of goutSeoyoung C Kim, Bernhard M W Schmidt, Jessica M Franklin, et al.
Seminars in Arthritis and Rheumatism|April 21, 2018
No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort studySeoyoung C Kim, Daniel H Solomon, James R Rogers, et al.
Journal of General Internal Medicine|June 8, 2021
Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020Sara Jane Cromer, Kristin M D'Silva, Elaine W Yu, et al.
Clinical and Experimental Rheumatology|December 14, 2021
Giant cell arteritis treatment patterns and rates of serious infectionsSara K Tedeschi, Yinzhu Jin, Seanna Vine, et al.
Osteoarthritis and Cartilage Open|May 7, 2021
Knee osteonecrosis incidence from two real-world data sourcesJean W Liew, Seoyoung C Kim, Christine Peloquin, et al.
Diabetes Care|January 19, 2022
Three Sides to the Story: Adherence Trajectories During the First Year of SGLT2 Inhibitor Therapy Among Medicare BeneficiariesChelsea E Hawley, Julie C Lauffenburger, Julie M Paik, et al.
Pageof 19